FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair value, assets measured on recurring basis

	Fair Value Measurement at December 31, 2022
	Total		Level 1		Level 2		Level 3
Investment in common stock of Alzamend Neuro, Inc. (“Alzamend”) – a related party	$	6,449,000	$	6,449,000	$	-	$	-
Investments in marketable equity securities		6,590,000		6,590,000		-		-
Cash and marketable securities held in trust account		118,193,000		118,193,000		-		-
Investments in other equity securities		13,340,000		-		-		13,340,000
Total assets measured at fair value	$	144,572,000	$	131,232,000	$	-	$	13,340,000

	Fair Value Measurement at December 31, 2021
	Total		Level 1		Level 2		Level 3
Investment in common stock of Alzamend – a related party	$	13,230,000	$	13,230,000	$	-	$	-
Investments in marketable equity securities		40,380,000		40,380,000		-		-
Cash and marketable securities held in trust account		116,725,000		116,725,000		-		-
Investments in other equity securities		9,215,000		-		-		9,215,000
Total assets measured at fair value	$	179,550,000	$	170,335,000	$	-	$	9,215,000

Schedule of investments

	Investments in other equity securities
Balance at January 1, 2022	$	9,215,000
Investment in preferred stock		11,566,000
Change in fair value of financial instruments		34,118,000
Conversion to marketable securities		(41,560,000	)
Balance at December 31, 2022	$	13,339,000